Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 6628
- Evidence Id
- 6628
- Core Evidence Id
- 6628
- Source Clinical Trial Id
- 6615
- Herb2 Clinical Trial Id
- HBCT006615
- Nct Id
- NCT03475524
- Title
- USE THE SYSTEMIC METFORMIN IN MELASMA
- Status
- Phase
- Phase 4
- Study Result
- No
- Study Condition
- Melasma
- Study Type
- Interventional
- Study Design
- Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
- Intervention
- DRUG: MetFORMIN 1000 Mg Oral Tablet|DRUG: Placebos|DRUG: Trichloroacetic Acid Peeling|DRUG: MetFORMIN 500 Mg Oral Tablet
- Intervention Allocation
- Randomized
- Intervention Model
- Parallel
- Intervention Mask
- Double
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 60
- Outcome Measure
- degree of improvement of melasma, Melasma Area and Severity Index score will be calculated for patients before and after treatment to all patientsscore is calculated by multiplying the area of involvement with the square of pigmentation as given in the formula: MSI = 0.4 (a × p 2 ) l + 0.4 (a × p 2 ) r + 0.2 (a × p 2 ) n In the formula, "a" stands for "area of involvement," "p" for "severity of pigmentation," "l" for left face, "r" for right face, and "n" for nose. The area involved, as well as the severity of pigmentation is scored from 0 to 4Score 0:No visible pigmentation,score 1 :rarely visible pigmentation scor e 2:mild pigmentation score3: moderate pigmentation score 4:sever pigmentation.scoringfor area of involvement less than or equal 10% area involved-scor1,11-30%-score2 ,31-60%-score3 and more than 60%-score 4 . patient will be photographed at baseline and after every two weeks interval and one month after the last session, up to 3 months
- Sponsor Collaborator
- Assiut University
- Funded By
- OTHER
- Location
- Assuit University, Assiut, 71111, Egypt
- Other Id
- MTM
- Start Date
- 2019-04-01
- Primary Completion Date
- 2021-08
- Completion Date
- 2021-08
- First Posted
- 2018-03-23
- Results First Posted
- Last Update Posted
- 2021-08-03
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT03475524
- Title Cn
- Title En
- USE THE SYSTEMIC METFORMIN IN MELASMA
- Bilingual Status
- semi_complete